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A B S T R A C T
Tau protein inclusions are a frequent hallmark of a variety of neurodegenerative disorders. The 10+16 intronic
mutation in MAPT gene, encoding tau, causes frontotemporal dementia and parkinsonism linked to
chromosome 17 (FTDP-17), by altering the splicing of the gene and inducing an increase in the production
of 4R tau isoforms, which are more prone to aggregation. However, the molecular mechanisms linking increased
4R tau to neurodegeneration are not well understood.
Here, we have used iPSC-derived neurons from patients of FTDP-17 carrying the 10+16 mutation to study
the molecular mechanisms underlying neurodegeneration.
We show that mitochondrial function is altered in the neurons of the patients. We found that FTDP-17
neurons present an increased mitochondrial membrane potential, which is partially maintained by the F1Fo
ATPase working in reverse mode. The 10+16 MAPT mutation is also associated with lower mitochondrial
NADH levels, partially supressed complex I-driven respiration, and lower ATP production by oxidative
phosphorylation, with cells relying on glycolysis to maintain ATP levels. Increased mitochondrial membrane
potential in FTDP-17 neurons leads to overproduction of the ROS in mitochondria, which in turn causes
oxidative stress and cell death. Mitochondrial ROS overproduction in these cells is a major trigger for neuronal
cell death and can be prevented by mitochondrial antioxidants
1. Introduction
Tau protein is implicated in the pathogenesis of several clinically
diverse neurodegenerative disorders collectively termed the tauopa-
thies. Although clinically heterogeneous, ranging from dementias such
as Alzheimer's disease (AD) or frontotemporal dementia (FTD) to
movement disorders such as progressive supranuclear palsy (PSP) or
corticobasal degeneration (CBD), they are all characterized by the
deposition of abnormal tau protein in diﬀerent regions of the brain
[40]. Tau is mostly expressed in the nervous system, especially in
neurons, and is implicated in microtubule assembly and stabilization
[44], being essential for morphogenesis, axonal extension or axonal
transport [4].
There are six isoforms of the protein expressed in the adult human
brain, generated by alternative splicing of exons 2, 3 and 10 of MAPT,
the gene that encodes tau [15]. The inclusion of exon 10 leads to tau
isoforms containing 4 microtubule-binding repeats (4R), while its
exclusion generates the 3R isoforms, containing 3 microtubule-binding
repeats. In a normal brain there is a similar proportion of 3R and 4R
isoforms [13,23]. However, certain MAPT mutations can cause in-
creased exon 10 inclusion, resulting in an overproduction of 4R
isoforms and an imbalance of the 3R/4R ratio, which is enough to
cause neurodegeneration and dementia [28]. This is the case of the
intronic 10+16 MAPT mutation, that causes frontotemporal dementia
with parkinsonism linked to chromosome 17 (FTDP-17). An imbalance
in the 3R/4R ratio is also observed in the sporadic tauopathies PSP and
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CBD.
The potential of induced pluripotent stem cells (iPSC) technology to
develop human neuronal models directly from patient's cells has
become a very useful tool to understand the pathogenic mechanisms
of neurodegenerative disorders linked to genetic mutations [32]. We
have recently shown that iPSC-derived cortical neurons from patients
with the 10+16 mutation in MAPT express both 3R and 4R tau, in
contrast to control neurons which express mainly 3R tau at early stages
of development [41]. At extended time-points, iPSC-derived neurons
recapitulate the tau expression and splicing patterns observed in
human brain development. Thus, this model represents a promising
approach for the study of the molecular mechanisms of tau pathology
occurring in FTD.
One of the several factors that can lead to neuronal loss in
neurodegenerative disorders is the dysfunction of the mitochondria.
In the present study we were focused on the analysis of the mitochon-
drial function and bioenergetics in iPSC-derived neurons from patients
of FTDP-17 carrying the MAPT 10+16 mutation. We show that the
10+16 MAPT mutation induces an impairment of the mitochondrial
function: neurons from the patients present alterations in the bioener-
getics, with a reduced NADH mitochondrial pool resulting in decreased
respiration, and a reduction of the ATP produced by oxidative
phosphorylation which is compensated by an increased production of
ATP by glycolysis. 10+16 MAPT mutation is also associated with a
higher mitochondrial membrane potential that leads to an increase in
ROS production, oxidative stress and ultimately cell death.
2. Materials and methods
2.1. Cell lines
Experiments were performed with 4 diﬀerent cell lines. The hESC
control line Shef6 was obtained from UK Stem Cell Bank. The two
patient iPSC lines were generated by retroviral-transduction repro-
gramming of ﬁbroblasts obtained from the National Hospital for
Neurology and Neurosurgery and the control iPSC line, also generated
using retroviral transduction, was obtained from the laboratory of Dr
Tilo Kunath. All the information regarding the reprogramming of
ﬁbroblasts into iPSC and characterization of the lines can be found in
[41].
Diﬀerentiation of the iPSC into cortical neurons was done using
dual SMAD inhibition followed by in vitro neurogenesis as described in
[37,41].
30–40 days after induction, cells were plated in poly-ornithine/
laminin coated μ-Slide 8 well Ibidi chambers (Martinsried, Germany).
Cells were then maintained in neural maintenance media described in
[37], with media changes twice a week. All the experiments were
performed in neurons older than 80 days (after induction).
2.2. Live imaging
All experiments were done in commercial HBSS 1X (with calcium
and magnesium) (ThermoFisher) supplemented with 10 mM HEPES
and adjusted to pH 7.4.
2.2.1. Measurement of mitochondrial membrane potential
Cells were incubated at room temperature for 40 min with 25 nM
tetramethylrhodamine methyl ester (TMRM), and when necessary for
mitochondrial mass measurements with Calcein-AM (1 μM, Molecular
Probes, ThermoFisher) and 0.005% Pluronic. Images were acquired
using a Zeiss 710 VIS CLMS confocal microscope equipped with a
META detection system and an x40 oil immersion objective (Zeiss,
Oberkochen, Germany). The 560 nm laser line was used to excite the
TMRM and the 488 nm to excite calcein. Emitted ﬂuorescence was
measured above 580 nm for TMRM and between 500 and 540 nm for
calcein, keeping the power laser at minimum to avoid phototoxicity. Z-
stacks were acquired for the calculations of the mitochondrial mem-
brane potential and mass. Images were analysed using Volocity 3D
Image Analysis Software (PerkinElmer, Waltham, MA, USA). Data was
obtained from n=9–38 Z-Stacks in 6–12 independent experiments
done with diﬀerent inductions, and was normalized to control cells in
all of them. For ΔΨm maintenance experiments, a single focal plane
was selected and TMRM intensity was measured during the appro-
priate amount of time. TMRM was used in the redistribution mode, so
a reduction in TMRM signal represents mitochondrial depolarization.
Zeiss software was used for the analysis of the experiments. Basal
TMRM levels were taken as 100% and remaining TMRM ﬂuorescence
in the mitochondria after complete depolarization caused by FCCP was
taken as 0%. Data was obtained from n=26–40 cells analysed in 3–5
independent experiments done with diﬀerent inductions.
2.2.2. Measurement of NADH redox state
NADH autoﬂuorescence was measured using an epiﬂuorescence-
inverted microscope equipped with a x40 oil objective. A Xenon arc
lamp passed through a monochromator was used to provide excitation
light at 360 nm. Emitted light was reﬂected through a 455 nm long-
pass ﬁlter to a cooled CCD camera. Images were acquired and analysed
using Andor Software. After recording basal autoﬂuorescence, 1 μM
FCCP was added to completely depolarize the mitochondria and oxidize
the mitochondrial pool of NADH to NAD+, which is no longer
ﬂuorescent. This point was taken as 0%. 1 mM NaCN was then added
to inhibit respiration and allow the regeneration of the mitochondrial
pool of NADH (100%). NADH pool was calculated as the diﬀerence
between maximum and minimum values of autoﬂuorescence in the
mitochondria. NADH redox index was calculated as the % represented
by the basal levels when extrapolating its value in the 0–100% range
generated by FCCP and NaCN respectively. A total number of n=100–
200 cells were analysed in 4–7 independent experiments.
2.2.3. Measurement of glucose uptake
The ﬂuorescent glucose analogue 2-NBDG (Molecular Probes,
Thermoﬁsher) was used for glucose uptake experiments. Cells were
incubated in HBSS containing no glucose in the presence of 2 mM 2-
NBDG for 25 min. Cells were then washed and 4–5 z-stacks per well
were acquired using a Zeiss 710 VIS CLMS confocal microscope
equipped with a META detection system and an x40 oil immersion
objective (Zeiss, Oberkochen, Germany). The 488 nm laser was used to
excite 2-NBDG and emitted ﬂuorescence was measured above 495 nm.
Green ﬂuorescence inside the cells was quantiﬁed using Zeiss software.
At least 90 cells per line were analysed in a minimum of 5 independent
measurements.
2.2.4. Measurement of ATP
For the monitoring of ATP levels, cells were transfected with the
mitochondrial-targeted ATP indicator AT1.03, designed by [20]. This
genetically encoded FRET indicator allows the visualization of the
dynamics of ATP in real time. Brieﬂy, this probe contains a variant of
the cyan ﬂuorescent protein (CFP) and a variant of yellow ﬂuorescence
protein (YFP). When ATP is not bound to the probe, both ﬂuorescent
proteins are separated and the FRET eﬃciency is low, so ﬂuorescence
emitted from the CFP is the mainly detected. In contrast, when ATP
binds to the probe, the two ﬂuorescence proteins come close to each
other, increasing FRET eﬃciency, and as a result, YFP signal. Thus, the
YFP/CFP emission ratio is used to evaluate ratiometrically the levels of
ATP. Measurement of ATP levels with mitoAT1.03 probe was per-
formed on the confocal microscope Zeiss 710 LSM with an integrated
META-detection system using a 40x oil-immersion objective. CFP was
excited with 405 nm laser, and its emission was detected between 460–
510 nm. Emission from YFP was detected between 540–600 nm.
Cells were transfected using the Eﬀectene transfection reagent from
Qiagen (Hilden, Germany), following the manufacturer's indications.
AT1.03 cDNA was kindly provided by Prof Imamura from the Habuki
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Center & Graduate School of Biostudies, (Kyoto University, Japan).
Data was obtained from n=13–37 cells in 4–7 independent experi-
ments, and was normalized to control cells in all of them.
2.2.5. ROS production and lipid peroxidation
Cytosolic ROS production was monitored in single cells using the
superoxide indicator dihydroethidium (DHE, 2 μM, Molecular Probes,
ThermoFisher), which shows blue ﬂuorescence in the cytosol until
Fig. 1. Mitochondrial membrane potential is higher in patients with the MAPT 10+16 mutation and is partially maintained by complex V working in reverse
mode. 1A. Mitochondrial membrane potential (ΔΨm) was estimated using tetramethylrhodamine methyl ester (TMRM) indicator. Neurons from the patients with 10+16 MAPT
mutation showed a signiﬁcant increase in ΔΨm compared to controls (*p < 0.05, ***p < 0.001). 1B. Mitochondrial mass was lower in the neurons from the patient (*p < 0.05) as
estimated by the percentage of the cell occupied by mitochondria (stained with TMRM) in relation to the total volume of the cell (stained with calcein). 1C. Representative images from
live imaging experiments showing the TMRM (red) and calcein (green) staining. Scale bar: 20 µm. 1D. Time-course experiments of TMRM signal showing the maintenance of the ΔΨm
in the presence of inhibitors of diﬀerent mitochondrial complexes. Oligomycin (inhibitor of complex V) didn’t aﬀect the ΔΨm in the control cells but induced a partial depolarization in
patient cells. Inhibition of complex I with rotenone induced a strong depolarization in control cells that was much smaller in patient's cells, and FCCP led to the complete depolarization
in both cases, showing that contribution of complex II to the maintenance of ΔΨm was higher in patient cells than in controls.
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oxidized, when it intercalates within the DNA, staining the nucleus
ﬂuorescent red. Live-imaging experiments were performed in an
epiﬂuorescence inverted microscope using a Xenon arc lamp passed
through a monochromator to provide excitation light at 530 nm.
Emitted light was reﬂected through a 605 nm long-pass ﬁlter to a
cooled CCD camera. Cells were loaded with DHE and basal rate of ROS
production, measured as the rate of increase in red DHE ﬂuorescence,
was immediately recorded for several minutes. Images were captured
and analysed using IQ2 software from Andor. Around n=100–200 cells
were analysed in at least four independent experiments.
Mitochondrial ROS production was analysed using the mitochon-
drial-targeted dye MitoTracker® Red CM-H2XRos (Molecular Probes,
Thermoﬁsher). Cells were loaded for 20 min with the dye, and
measurements were done on the confocal microscope Zeiss 710 LSM
with an integrated META-detection system using a 40x oil-immersion
objective. The dye was excited with 561 nm laser, and emission was
detected above 580 nm and recorded for several minutes. The rate of
increase in red ﬂuorescence for each whole ﬁeld was analysed using
Volocity 3D Image Analysis Software (PerkinElmer, Waltham, MA,
USA). N=4–11 ﬁelds containing at least 100 cells each were analysed in
4–6 independent experiments.
Lipid peroxidation was measured in single cells with Bodipy 581/
591 C11 (2 μM, Molecular Probes, ThermoFisher) on the confocal
microscope Zeiss 710 LSM with an integrated META-detection system
using a 40x oil-immersion objective. Bodipy 581/591 C11 is a
ﬂuorescent fatty acid analogue that incorporates into cellular mem-
branes and shows ﬂuorescence in the red range of the spectrum
(~590 nm). Upon oxidation, the ﬂuorescent properties shift from red
to green (~520 nm), allowing the ratiometric measurement of lipid
peroxidation. Bodipy was excited using the 488 nm and 561 nm laser
lines and ﬂuorescence detected in 500–550 nm and 575–680 nm.
Images were acquired and analysed using Zeiss software. The rate of
the increase of the Bodipy ratio (green/red) was calculated in n=50–
200 cells in at least 3 diﬀerent experiments.
2.2.6. Cell death
Cells were loaded with 20 μM propidium iodide and 10 μMHoechst
33342. While Hoechst is a blue ﬂuorescent dye that stains chromatin
DNA, propidium iodide is only permeable to dead cells and shows red
ﬂuorescence, so it is possible to calculate the percentage of dead cells
(showing red ﬂuorescence) vs. total number of cells (showing blue
ﬂuorescence). Images were acquired in the Zeiss 710 LSM confocal
microscope with an integrated META-detection system using a 20x
objective and analysed using ImageJ software. A total number of 500–
2000 cells were counted in n=18–28 diﬀerent ﬁelds. Experiments were
repeated at least 3 times with diﬀerent inductions.
2.3. Statistics
All histograms represent the average ± SEM. Statistical analysis
(One-way ANOVA followed by Tukey post-hoc correction) was per-
formed in OriginPro 2016 software. Diﬀerences were considered to be
signiﬁcant if p < 0.05.
3. Results
3.1. 10+16 MAPT mutation is associated with higher mitochondrial
membrane potential partially maintained by complex V
To study if the MAPT 10+16 mutation aﬀects mitochondrial
function, we used as a model iPSC-derived neurons from two FTDP-
17 patients carrying the speciﬁc intronic mutation together with a
control iPSC line and from a human embryonic stem cell line (hESC)
[41].
We ﬁrst measured mitochondrial membrane potential (ΔΨm) as it
represents a good indicator of the health of the cells and alterations in
ΔΨm are frequently found in neurodegenerative disorders. We loaded
the cells with tetramethylrhodamine methyl ester (TMRM) and used
live imaging to estimate the ΔΨm. Surprisingly, we found that the iPSC-
derived neurons from the patients of FTDP-17 show an increase in
ΔΨm compared to both iPSC and hESC-derived neurons from healthy
controls, as suggested by the signiﬁcantly higher TMRM signal
(Fig. 1A). Compared to the control lines (100 ± 2.5% (iPSC control,
n=47) and 103.5 ± 2.3% (hESC control, n=9)) the neurons from the
patients with the mutation in MAPT showed an increase in TMRM
intensity to 135.8 ± 6% (patient 1, n=38) and 128.6 ± 4.6% (patient 2,
n=19). The mitochondrial mass, calculated as the percentage of the
volume occupied by mitochondria (stained with TMRM) in the total
volume of the cell (stained with calcein), appeared to be lower in the
patients (Fig. 1B) (patient 1, 88.9 ± 3.4%, n=14; patient 2, 82.2 ± 5.7%,
n=11) compared to the controls (100 ± 3.2%, n=18 and 101.8 ± 9.1%,
n=3; Fig. 1B). Representative images of calcein and TMRM staining
can be found in Fig. 1C.
We next examined the mechanism by which ΔΨm was maintained
in these cells. In healthy mitochondria, ΔΨm is maintained by the
pumping of protons from the matrix to the intermembrane space
through the complexes of the electron transport chain. The protons
then cross back to the matrix through the ATP synthase (complex V),
and the energy derived from the proton-motive force is used to
generate ATP. However, in case of pathology, complex V can work in
reverse mode, hydrolysing ATP and pumping protons to the inter-
membrane space. To test the contribution of each of the complexes to
the maintenance of the ΔΨm, we ﬁrst treated the neurons with the
complex V inhibitor, oligomycin (2 μg/mL). As shown in Fig. 1D,
control iPSC-derived neurons showed no response to oligomycin (2.95
± 3.76% decrease of the TMRM signal, n=40), while patients showed a
signiﬁcant decrease in the TMRM signal, suggesting that in these cells,
complex V is working in reverse to maintain the ΔΨm (patient 1, 28.4 ±
4.8%, n=26; patient 2, 19.9 ± 3.6%, n=29). The subsequent inhibition
of complex I by rotenone (5 μM) caused a deep decrease in the TMRM
signal in healthy controls (78.2 ± 4.1), that was much smaller in the
patients (patient 1, 41.9 ± 3.4%; patient 2, 43.5 ± 2.9%). Treatment of
the cells with the uncoupler FCCP (1 μM) completely depolarised the
mitochondria, causing a further decrease in the ΔΨm which indicates
the contribution of complex II. In the cells from the patients, the
response to FCCP appeared to be higher than in control cells,
suggesting a possible compensating mechanism of complex II for the
decreased contribution of complex I (control, 19.9 ± 3.6%; patient 1,
43.5 ± 2.9%; patient 2, 36.7 ± 3.7%).
These results indicate that the electron transport chain activity is
not suﬃcient to maintain the ΔΨm in the cells of the patients with the
mutation in MAPT. Instead, complex V working in reverse partially
maintains the ΔΨm, with reduced complex I and increased complex II
contributions.
3.2. The MAPT 10+16 mutation is associated with a more reduced
NADH redox state and lower mitochondrial NADH pool
We next examined the respiratory function by analysing the redox
state of NADH, as an indicator of the activity of respiratory complex I,
representative traces are shown in Fig. 2A. NADH redox state was
calculated as the percentage of the basal mitochondrial NADH auto-
ﬂuorescence, in a scale were 0% represents the maximally oxidized
NADH (obtained after depolarising the mitochondria with FCCP 1 µM)
and 100% represents the maximally reduced NADH (obtained after
inhibiting respiration with NaCN 1 mM, and therefore allowing the
regeneration of the mitochondrial pool of NADH), as described in [5].
Cells from patients show a signiﬁcantly higher (more reduced) redox
index than control cells (Fig. 2B), suggesting that complex I-driven
respiration is inhibited in mutant cells compared to the controls (iPSC
control, 45.9 ± 1.1%, n=212 cells; hESC control, 51.7 ± 1.3%, n=108
cells; patient 1, 63.7 ± 1.9%, n=127 cells; patient 2, 62.9 ± 1.6%, n=103
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Fig. 2. Mitochondrial NADH pool is lower and complex I-driven respiration is inhibited in iPSC-derived neurons from patients with theMAPT 10+16 mutation.
2A. Representative traces of NADH status experiments. Basal autoﬂuorescence of NADH was measured prior to the addition of FCCP to complete depolarize the mitochondria,
stimulating respiration and causing the complete oxidation of NADH to NAD+, which is no longer ﬂuorescent. This point was considered as 0%. NaCN was then added to inhibit
respiration and allow the complete regeneration of mitochondrial NADH pool (maximally reduced), taken as 100%. Basal NADH redox state (%) was extrapolated from the 0–100%
range and mitochondrial NADH pool was calculated as the diﬀerence between min and max autoﬂuorescence. 2B. NADH Redox Index is higher (i.e. more reduced) in patients carrying
the 10+16MAPTmutation (***p < 0.001), suggesting the inhibition of complex I-driven respiration. 2C. Mitochondrial NADH pool is lower in neurons from the patients (***p < 0.001).
2D. Quantiﬁcation of glucose uptake by the cells using the ﬂuorescent glucose analogue 2-NBDG as described in Methods.
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cells). One of the reasons that may explain this situation could be a
lower availability of substrates for respiration coming from the TCA
cycle. Indeed, as presented in Fig. 2C, cells from patients show a lower
total mitochondrial NADH pool than control cells (iPSC control, 100 ±
2.5%; hESC control, 117 ± 3.7%; patient 1, 84.5 ± 2.1; patient 2, 66.5 ±
2.2), which suggests that inhibition of respiration in patient cells may
be due to a diminished availability of NADH for complex I.
One of the reasons for the lower availability of substrates for
respiration could be an alteration in the glucose uptake in these cells
that may aﬀect the downstream metabolism. To investigate it, we
studied the uptake of the ﬂuorescent glucose analogue 2-NBDG (2 mM)
by the cells in HBSS media containing no glucose. As shown in Fig. 2D,
the uptake of 2-NBDG was similar in all the cell lines (control iPSC
95.2 ± 2.7%, n=115; control hESC 104.5 ± 2.7%, n=118; patient 1 96.4
± 2%, n=101; patient 2 96.3 ± 2.3%, n=90), excluding the possibility of
an altered glucose uptake in these cells as the reason for the
bioenergetics alterations found.
3.3. ATP levels are similar in control and patient cells, but glycolysis
is the main source of ATP in the cells with the MAPT 10+16 mutation
Mitochondrial respiration is closely coupled to ATP production by
oxidative phosphorylation (OXPHOS), so impairment in the respira-
tion may also aﬀect ATP production in neurons with the MAPT 10+16
mutation. To evaluate the dynamics and levels of ATP, we transfected
the iPSC-derived neurons with the mitochondrial ratiometric ATP
indicator designed by [20] (AT1.03) which allows to detect ATP levels
in living cells as described in Methods. Despite the lower rates of
respiration, neurons from the patients presented similar mitochondrial
ATP levels than control neurons (iPSC control, 99.8 ± 3.5%, n=37 cells;
hESC control, 100.3 ± 3.4%, n=14 cells; patient 1, 94.5 ± 2.3%, n=40
cells, patient 2, 99.4 ± 3%, n=13 cells) (Fig. 3B).
To have a better understanding of ATP dynamics in this model, we
next checked the functioning of the mechanisms of ATP production.
There are two main cellular systems implicated in ATP production:
glycolysis and oxidative phosphorylation. To study how each of them
was contributing to ATP production in the neurons, we sequentially
treated them with the inhibitor of complex V oligomycin, and the
inhibitor of glycolysis iodoacetic acid (IAA), and analysed the decay in
the ATP levels caused by the inhibition of each mechanism, represen-
tative traces are shown in 3A. In control cells, inhibition of OXPHOS
caused a decay in the ATP levels of 57.3 ± 6.1% and 46.8 ± 5%, with a
further decrease of 42.7 ± 6.1 and 53.2 ± 5% after inhibition of
glycolysis with IAA (iPSC control cells, n=21 and hESC, n=4, respec-
tively) (Fig. 3C). In contrast, in patient cells, ATP production was
mainly dependent on glycolysis as observed by the drop in ATP caused
by IAA (patient 1, 89.7 ± 4%; patient 2, 99.4 ± 3%). Complex V
inhibition in patient cells produced either a small decrease or a small
increase in ATP levels (patient 1, 10.3 ± 4.1%, n=28; patient 2, 1.7 ±
3%, n=8), which can be explained by the inhibition of the hydrolysis of
ATP by the F1FoATPase working in reverse mode, in agreement with
the results shown in Fig. 1D. Results presented in Fig. 3 suggest that
the neurons from the patients depend on glycolysis to maintain the
ATP levels, rather than on OXPHOS, which is the main source of ATP
in iPSC control neurons.
3.4. Provision of cells with substrates for TCA cycle increases
mitochondrial NADH pool and recuperates the altered bioenergetics
features
An enhancement of the production of ATP by glycolysis could be a
compensatory mechanism for the decreased production of ATP by
OXPHOS in iPSC-derived neurons from patients with the mutation in
MAPT, with the lack of substrates for respiration (Fig. 2C) being the
possible underlying cause. To test this possibility, we supplied the cells
with pyruvate, to serve as a substrate for the TCA cycle, and checked
how ATP was produced under these circumstances; representative
traces are shown in Fig. 4A. When patient cells were pre-incubated
with 5 mM sodium pyruvate (NaPyr), inhibition of OXPHOS with
oligomycin caused a decrease in the ATP levels that was signiﬁcantly
higher than in non pre-treated cells (Fig. 4B: patient 1, pretreated with
NaPyr, 57.6 ± 9.5%, n=11 vs. non pretreated, 10.7 ± 5.1%, n=8; patient
2, pretreated with NaPyr, 19.2 ± 2.1%, n=4 vs. non pretreated 2.3 ±
5.6%, n=4). In parallel, the % of ATP produced by glycolysis was
reduced when the patients’ cells were provided with pyruvate (Fig. 4B:
patient 1, pretreated with NaPyr, 42.4 ± 9.5% vs. non pretreated, 89.3
± 5.1%; patient 2, pretreated with NaPyr, 80.8 ± 2.1% vs. non pre-
treated, 97.7 ± 5.6%). These results show that in the presence of
substrates for the TCA cycle, patient's cells are able to increase their
production of ATP by OXPHOS, reducing the ATP produced by
glycolysis.
We then conﬁrmed how provision of substrates for the TCA cycle
was indeed aﬀecting the respiratory activity, by analysing the NADH
redox state in the presence and absence of sodium pyruvate (repre-
sentative traces are depicted in Fig. 4C). As shown in Fig. 4D, when
cells from the patients were incubated with 5 mM of NaPyr, NADH
redox index signiﬁcantly diminished (was more oxidized) in patient 1
from 64.4 ± 2.6% (non treated, n=33) to 47.1 ± 2.4% (treated, n=49)
and in patient 2 from 75.4 ± 2.9% (non treated, n=22) to 52.1 ± 1.5%
(treated, n=32) (Fig. 4D), indicating that respiration was increased in
the presence of substrates for the TCA cycle. Accordingly, the pool of
mitochondrial NADH also increased signiﬁcantly in the presence of
sodium pyruvate in the neurons of the patients (Fig. 4E) (patient 1, non
treated, 86.4 ± 2.4%, vs. treated, 103.3 ± 6%; patient 2, non treated
75.4 ± 4.4% vs. treated, 104.1 ± 5%).
Importantly, we also conﬁrmed that the provision of substrates for
TCA cycle to the iPSC-derived neurons from FTDP-17 patients
completely prevented the oligomycin-induced depolarization of the
mitochondrial membrane potential (representative traces shown in
Fig. 4F). Drop in ΔΨm produced by oligomycin decreased from 22 ± 9.1
(patient 1, n=4) and 16.4 ± 2.7% (patient 2, n=15), to 2.2 ± 9.6%
(patient 1, n=10) and −7.5 ± 6 (hyperpolarization) in patient 2 (n=15)
when cells were pre-treated with NaPyr.
Taken together, these data indicates that in the presence of
substrates for the TCA cycle like pyruvate, mitochondrial NADH pool
is recovered in iPSC-derived neurons from patients, which turns into
higher rates of respiration and ATP produced by oxidative phosphor-
ylation instead of glycolysis. In addition, the electron transport chain is
able to maintain the ΔΨm, which is no longer maintained by the
complex V working in reverse mode.
3.5. ROS production is increased in iPSC-derived neurons carrying
the MAPT 10+16 mutation
Despite the partial inhibition of the respiration in patient's cells
ATP production is compensated by glycolysis. Considering this, energy
deprivation in these cells is unlikely to be a main mechanism of cell
death. Reactive oxygen species (ROS) are implicated in the regulation
of important physiological functions in the cell [2,3]. However, over-
production of ROS is considered to play a central role in the
pathogenesis of neurodegenerative disorders [11]. Mitochondria are
one of the most important intracellular sources of ROS, and both
higher mitochondrial membrane potential and alterations in the
electron transport chain (as found in iPSC-derived neurons of the
patients) can lead to an increase in ROS production [1]. We investi-
gated this feature by measuring the rate of ROS production both in the
cytosol and in the mitochondria of the cells. For the ﬁrst, we used
dihydroethidium (DHE), which is a cytosolic ROS indicator predomi-
nantly speciﬁc for superoxide. Rate of increase in DHE ﬂuorescence
upon oxidation of the dye is proportional to the rate of superoxide
generation (representative traces in Fig. 5A.) Neurons derived from the
patients with 10+16 MAPT mutation presented a signiﬁcantly higher
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Fig. 3. ATP levels are similar in control and patient cells, but glycolysis is the main source of ATP in the cells of the patients with theMAPT 10+16 mutation. 3A.
Representative traces showing ATP live measurements. Cells were transfected with AT1.03 probe allowing the visualization of mitochondrial ATP in vivo. After measurement of basal
levels of ATP (ratio YCF/CFP), oligomycin was added to inhibit complex V. The subsequent reduction in ATP levels can be attributed to ATP generated by oxidative phosphorylation
(OXPHOS). Decrease in ATP levels caused by the following addition of iodoacetic acid can be attributed to ATP generated by glycolysis. 3B. Basal measurements of ATP levels show no
diﬀerence between controls and patient cells. 3C. Percentage of ATP produced by OXPHOS or glycolysis, calculated by the percentage of decay caused by each inhibitor. In cells from
patients with MAPT 10+16 mutation, ATP is mainly produced by glycolysis. (**p < 0.01, ***p < 0.001).
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rate of cytosolic ROS production compared to the controls (Fig. 5B,
iPSC Control, 101.4 ± 3.2%, n=152; hESC control, 97.5 ± 5%, n=84;
patient 1, 132.4 ± 3.7%, n=224; patient 2, 154 ± 6.1%, n=112). The
same principle was used to measure the rate of mitochondrial ROS
production. To this end, we employed the mitochondrial-targeted dye
MitoTracker® Red CM-H2XRos, which is a reduced probe that is non-
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ﬂuorescent until it is oxidized. Fig. 5C shows that the rate of
mitochondrial ROS production, calculated as the rate of increase in
red ﬂuorescence of the dye, is also signiﬁcantly increased in the
neurons from the patients compared to the controls (iPSC control,
94.4 ± 5.5%, n=6 measurements; hESC control, 82.9 ± 17%, n=4;
patient 1, 162.3 ± 15%, n=11; patient 2, 163.9 ± 23%, n=6). To test
the speciﬁcity of the dye, we also pre-treated cells of the patients with
the mitochondria-targeted antioxidant mitoquinone (MitoQ) [22],
which induced a dramatic decrease in the rate of mitochondrial ROS
production (Fig. 5C).
When imbalanced and not controlled, overproduction of ROS can
lead to oxidative stress, which results in damage to macromolecules,
membranes and organelles that can be deleterious. Among others, ROS
can react with the polyunsaturated fatty acids of lipid membranes,
inducing lipid peroxidation, which can also amplify the damage to
other macromolecules. We used the ratiometric indicator Bodipy 581/
591 C11 to measure the rate of lipid peroxidation. Upon oxidation, the
ﬂuorescent properties shift from red to green, allowing the ratiometric
measurement of lipid peroxidation (representative traces and images
found in Fig. 5D and E). As shown in 5F, the basal rate of lipid
peroxidation is signiﬁcantly increased in the neurons from the patients
(iPSC Control, 93.2 ± 3.8%, n=106 cells; hESC Control, 115 ± 3.1%,
n=48; patient 1, 183 ± 6.1%, n=211; patient 2, 173 ± 6.9%, n=181),
showing that neurons from the patients exhibit higher levels of
oxidative stress.
As mentioned before, both the higher mitochondrial membrane
potential and alterations in the activity of the respiratory chain can
induce an increase in ROS production. To study both mechanisms, we
measured the changes in the rate of ROS production using DHE in the
presence of a substrate of complex I (5 mM NaPyr) to increase
respiration, or in the presence of the complex I inhibitor 5 μM
rotenone.
As shown in the representative traces found in Fig. 5F, in the
control cells, the application of NaPyr increased the basal rate of ROS
production from 96.1 ± 3.7% to 119.6 ± 3.5%, with a further increase to
132.4 ± 5.9% when complex I was inhibited with rotenone (n=123).
The cells of the patients, in agreement with Fig. 5B, showed an already
increased basal rate of ROS production compared to the controls
(patient 1, 167.3 ± 5.4%, n=132; patient 2, 200.6 ± 16.8%, n=29). In
those cells, application of NaPyr slightly increased the rate of ROS
production (to 153.8 ± 5% in patient 1 and to 205 ± 18% in patient 2)
and, in contrast with control cells, rotenone clearly diminished the rate
of ROS production to 129 ± 5.4% in patient 1 and to 155.8 ± 19% in
patient 2. These results suggest that in the iPSC-derived neurons from
the patients with the 10+16 MAPT mutation the higher rate of ROS
production is sustained by the higher mitochondrial membrane
potential rather than by the alterations in the respiratory chain.
3.6. Cell death is increased in neurons with the MAPT 10+16
mutation and is dependent on ROS production
Excessive ROS production can lead to cell death and neurodegen-
eration, so we next analysed the cell viability and its dependence on the
overproduction of ROS in the neurons from the patients. To this end,
we co-stained the cells with propidium iodide, which labels dead cells,
and Hoechst, which labels all cells, and calculated the percentage of cell
toxicity. Representative images are shown in 6B–D. Compared to
controls (iPSC control, 9.4 ± 1.2%, n=27; hESC control, 11.6 ± 1.4%,
n=19), cells from the patients showed signiﬁcantly higher basal levels
of cell death (patient 1, 24.8 ± 2.7%, n=28; patient 2, 24.2 ± 2.8%,
n=2=18), Fig. 6A. Importantly, when we treated the cells of the
patients with the mitochondria-targeted antioxidant MitoQ (48 h),
which was previously shown to decrease the mitochondrial ROS
production in these cells (Fig. 5C), the percentage of dead cells
decreased signiﬁcantly, as shown in Fig. 6A (patient 1+MitoQ, 12.4 ±
1%, n=21; patient 2+MitoQ, 13.8 ± 1.5%, n=10). These results suggest
that the excessive ROS production in the cells of the patients, linked to
the increased mitochondrial membrane potential, is the underlying
cause of the higher cell death found in this model and can be prevented
in vitro by inhibiting mitochondrial ROS production.
4. Discussion
Due to its role in promoting microtubule assembly, recent publica-
tions analysing the relationship between tau and mitochondria in iPSC-
derived neurons with MAPT mutations have focused on the alterations
of the axonal transport, vesicle traﬃcking, mitochondria distribution or
neurite growth, as reviewed in [32]. In the present study, we have used
iPSC-derived neurons carrying the 10+16 MAPT mutation to explore
for the ﬁrst time the mitochondrial bioenergetics and dysfunction
caused by tau pathology. We have found that the 10+16 MAPT
mutation is linked to the hyperpolarization of the mitochondria, which
is partially maintained by the complex V working in reverse, leading to
an increase in ROS production, oxidative stress and cell death.
Moreover, mitochondrial NADH pool is reduced and complex I-driven
respiration inhibited, causing a decrease in the ATP production by
oxidative phosphorylation that is compensated by an increase in
glycolysis.
Mitochondrial dysfunction is a common pathological feature of
neurodegenerative disorders and is often characterized by a decrease in
the mitochondrial membrane potential [9], which has also been
observed in diﬀerent models of tauopathies [6,36]. Here, we show that
despite their reduced mitochondrial respiration, the iPSC-derived
neurons from the patients carrying the 10+16 MAPT mutation present
an increase in the mitochondrial membrane potential that is partially
maintained by the complex V working in reverse mode: pumping
protons to the intermembrane space at the expense of ATP hydrolysis.
Although surprising, hyperpolarization of the mitochondria has been
described before in cells with reduced activity of complex I [1,10].
Interestingly, a higher ΔΨm has also been observed in isolated
mitochondria from the P301L tau mice model [7] and in iPSC-derived
motor neurons of the C9ORF72 model of ALS/FTD [29].
One possible explanation of the increased ΔΨm could involve
VDAC (voltage-dependent anion channel). VDAC is present in the
mitochondrial outer membrane and regulates the exchange of meta-
bolites between the cytosol and the mitochondria [26]. It has been
described that free tubulin binds VDAC [35] and is able to modulate
ΔΨm: an increase in free tubulin blocks VDAC and diminishes ΔΨm,
while a decrease opens VDAC increasing ΔΨm [30]. 4R isoforms of tau
are more eﬀective at assembling microtubules, (which are made of α
and β-tubulin dimers) leading probably to a decrease in free tubulin
compared to 3R isoforms, and to a potential opening of VDAC that
could contribute to the hyperpolarization of the mitochondria.
Impairment of complex I, mitochondrial respiration and oxidative
phosphorylation have been previously described for other models of
tau pathology, normally leading to decreased ATP levels [6,34,36].
Our data indicates that the lower availability of mitochondrial
NADH for the complex I results in a diminished mitochondrial
Fig. 4. Provision of patient cells with substrates for TCA cycle increases the mitochondrial NADH pool and recuperates the altered bioenergetics features. 4A.
Representative traces of ATP live measurements with the ATP AT1.03 construct. 4B. Quantiﬁcation of the percentage of ATP produced by oxidative phosphorylation (OXPHOS) (as
calculated by the drop in ATP levels caused by oligomycin) and glycolysis (% drop caused by iodoacetic acid) in the cells of the patients in the presence/absence of 5 mM sodium pyruvate
(NaPyr) (**p < 0.01, ***p < 0.001). 4C. Representative traces of NADH status experiments in patients cells pretreated or not with NaPyr 5 mM. 4D. Preincubation of the patient cells
with NaPyr decreased the NADH Redox index of patient cells to similar levels than controls (***p < 0.001). 4E. Preincubation of the cells of the patients with NaPyr signiﬁcantly
increased the mitochondrial NADH pool (*p < 0.05; ***p < 0.001). 4F. Representative traces of mitochondrial membrane potential maintenance in patients’ cells in the absence or
presence of NaPyr.
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respiration and altered ATP production by OXPHOS. Application of
pyruvate is able to reverse those defects, providing mitochondrial
NADH and increasing respiration. As a result, the cells switch back
to oxidative phosphorylation as a source of ATP production and
complex V stops working in reverse to maintain the ΔΨm, which is
maintained by the electron transport chain in the presence of pyruvate.
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These results suggest that the functionality of respiratory complexes is
maintained in the presence of 10+16 MAPT mutation and the reason
for the observed lower activity of complex I can be attributed to a
diminished availability of substrates. Pyruvate is able to correct the
defects shown above, indicating that the lack of substrates for respira-
tion is not caused either by alterations in the TCA cycle. As shown,
glucose uptake is not aﬀected by the MAPT mutation and glycolysis is
eﬃciently producing ATP as a compensatory mechanism for the
decreased OXPHOS, so one possible mechanism that can be altered
in the cells of the patients is the activity of the pyruvate dehydrogenase
(PDH) complex, which regulates the conversion of pyruvate, the ﬁnal
product of glycolysis, into acetyl-CoA as a ﬁrst step to enter the TCA
cycle. Indeed, lower PDH activity has been shown in an animal model
and human brain with AD [38,45]. Inhibition of the PDH is achieved
through its phosphorylation by the diﬀerent isoforms of the pyruvate
dehydrogenase kinase (PDK), which plays an important role in con-
trolling metabolic pyruvate ﬂux [16] and can contribute to diﬀerent
neuropathological conditions [21]. Importantly, high concentrations of
pyruvate are able to inhibit PDK, thus activating PDH complex [16],
which can explain the recuperation of the bioenergetics alterations
when applying pyruvate to the cells of the patients with the MAPT
mutation.
It has also been described that PDH can be phosphorylated and
inactivated by the Alzheimer's disease-related tau protein kinase I
(TPKI) [18].
iPSC-derived neurons from the patients of FTDP-17 presented
similar levels of ATP despite the reduction in ATP production by
OXPHOS, due to an increase in the ATP production by glycolysis. A
shift from aerobic respiration to glycolytic metabolism has also been
described in several models of Alzheimer's disease as an attempt to
maintain ATP production in response to mitochondrial dysfunction
[17,24]. Interestingly, another study found a correlation between
spatial distribution of increased aerobic glycolysis and Aβ deposition
in brain tissue [43]. Glycolytic enzymes are elevated in AD brains [39]
and increased levels of lactate, the ﬁnal product of aerobic glycolysis
have been found in the brain of patients from PSP -another 4R
tauopathy- [42] and in the CSF of AD patients [27].
It has also been described that an increase in aerobic glycolysis due
to an overproduction of PDK1 (and therefore inhibition of PDH) in
nerve cells resulted in a protective eﬀect against β-amyloid toxicity,
linked to a reduction in mitochondrial respiration, ΔΨm and ROS,
without aﬀecting ATP levels [31,39]. However, long-term consequences
for neuronal survival of the metabolic shift from OXPHOS to glycolysis
may be deleterious. Maintenance of ATP levels despite impairment of
mitochondrial respiration has been described in P301L MAPT mice
brain, but resulting in a signiﬁcant decrease with aging [6]. Our data
show that iPSC-derived neurons from the patients are able to maintain
ATP levels relying on glycolysis still after 150 days in vitro, the most
Fig. 6. Cell death is increased in the cells with theMAPT 10+16 mutation and is dependent on ROS production. 6A. Histogram showing the percentage of cell death in
controls and patients in the absence or presence of the inhibitor of mitochondrial ROS, MitoQ, 100 nM.*p < 0.05, ***p < 0.001. 6(B–D). Representative images of control neurons (B),
patient neurons (C) and patient neurons treated with MitoQ (D) cell death experiments. Cell toxicity was estimated co-staining the cells with propidium iodide (red ﬂuorescence) which
labels dead cells, and Hoechst (blue ﬂuorescence) which labels all cells. Scale bar: 50 µm.
Fig. 5. ROS production and lipid peroxidation are increased in the cells of the patients with theMAPT 10+16 mutation. 5A. Representative traces showing the rate of
cytosolic ROS production as measured by the increase in DHE ﬂuorescence. 5B. Quantiﬁcation of the rate of DHE ﬂuorescence, indicating that basal rate of cytosolic ROS production is
higher in the cells of the patients compared to the controls (***p < 0.001). 5C. Quantiﬁcation of the rate of MitoTracker® Red CM-H2Xros, indicating that basal rate of mitochondrial
ROS production is increased in the cells of the patients compared to the controls (*p < 0.05). 5D. Representative traces showing the basal rate of lipid peroxidation in the cells using
Bodipy 581/591 C11. 5E. Representative images of C-11 Bodipy ﬂuorescence after 4 min of recording. Oxidation of the dye results in a shift of the ﬂuorescence emission peak from red
(~590 nm) to green (~520 nm). Scale bar: 20 µm. 5F. Quantiﬁcation of the rate of C-11 Bodipy (581/591), indicating that the basal rate of lipid peroxidation is increased in the cells of
the patients (**p < 0.01, ***p < 0.001). 5G. Traces showing the eﬀect of substrates (NaPyr) or inhibition of complex I (rotenone) on the rate of ROS production in control and patients
neurons.
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extended time-point used for the experiments. It would be interesting
to study if ATP levels are maintained at more extended time-points in
vitro.
Cell death was however increased in the neurons of the patients
with the 10+16MAPTmutation as a result of the increased rate of ROS
production in these cells. Higher levels of ROS production and
oxidative stress have been reported in diﬀerent animal and cellular
models withMAPT mutations [6,19,33], generally linked to alterations
in the electron transport chain. Recent work done in N279K and
V337M models of MAPT mutations in iPSC-derived neurons also
showed increased oxidative stress in response to respiration inhibition
[8]. However, we have found that the increased ROS production in the
iPSC-derived neurons with 10+16 MAPT mutation was not a result of
the impairment of complex I, but instead it was linked to the
hyperpolarization of the mitochondria, as shown by the reduction in
the rate of ROS production when inhibiting complex I with rotenone.
As for mitochondrial membrane potential, diﬀerences in the observed
phenotype among models with diﬀerent MAPT mutations shouldn’t be
surprising giving the wide range of pathologies caused by the diﬀerent
MAPT mutations or even the clinical variability within members of a
family with the same mutation [12,14].
Importantly, cell death found in the neurons of the patients was
dependent on the increased ROS production, and it could be prevented
when treating the patient's cells with the mitochondria-targeted
antioxidant MitoQ, which is able to directly scavenge peroxynitrite
and superoxide, protecting mitochondria from lipid peroxidation [25].
These results are in agreement with recent work from [29] which also
showed that antioxidants could prevent the age-dependent oxidative
stress-induced damage in iPSC-derived motor-neurons from ALS/FTD.
In summary, our data provide the ﬁrst study focused on the
bioenergetics and mitochondrial dysfunction caused by tau pathology
in iPSC-derived neurons from patients with FTDP-17. Here, we have
given new insights to unravel the mechanisms of tau-related neurode-
generation and potential therapeutic strategies for FTDP-17.
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